Your search for tofacitinib returned 15 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Older than 2 years remove
MPR First Report remove

Your search for tofacitinib returned 15 results

Sort Results:

Relevant Recent
AIBD 2019

Combination Biologics or Small Molecules vs Biologic Monotherapy in IBD

The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
AIBD 2019

Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis

In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
AIBD 2019

Case Highlights Novel Approach to Treatment of UC, Psoriatic Arthritis

A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
AIBD 2019

Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined

Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.